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Glomuvenous malformations (GVMs) are cutaneous venous lesions characterized by the presence of smooth-
muscle–like glomus cells in the media surrounding distended vascular lumens. We have shown that heritable GVMs
link to a 4–6-cM region in chromosome 1p21-22. We also identified linkage disequilibrium that allowed a narrowing
of this VMGLOM locus to 1.48 Mb. Herein, we report the identification of the mutated gene, glomulin, localized
on the basis of the YAC and PAC maps. An incomplete cDNA sequence for glomulin had previously been designated
“FAP48,” for “FKBP-associated protein of 48 kD.” The complete cDNA for glomulin contains an open reading
frame of 1,785 nt encoding a predicted protein of 68 kD. The gene consists of 19 exons in which we identified
14 different germline mutations in patients with GVM. In addition, we found a somatic “second hit” mutation in
affected tissue of a patient with an inherited genomic deletion. Since all but one of the mutations result in premature
stop codons, and since the localized nature of the lesions could be explained by Knudson’s two-hit model, GVMs
are likely caused by complete loss of function of glomulin. The abnormal phenotype of vascular smooth-muscle
cells (VSMCs) in GVMs suggests that glomulin plays an important role in differentiation of these cells—and,
thereby, in vascular morphogenesis—especially in cutaneous veins.
Introduction
Venous malformations (VMs) are localized defects of
vascular morphogenesis that present as multiple bluish-
purple lesions, mainly in skin and mucosa. The lesions
can be single or multiple, varying in size from a small
blue spot to an extensive abnormality (Enjolras and
Mulliken 1996). They are often present at birth and
grow proportionally with the patient (Mulliken 1988).
Histologically, they show enlarged endothelial-lined
veinlike channels with defects in the smooth-muscle cell
(SMC) layer (Vikkula et al. 1996). These lesions are
commonly seen in centers that specialize in treatment of
vascular anomalies. Most appear to be sporadic, but
they can also be dominantly inherited (Boon et al. 1994;
Gallione et al. 1995; Vikkula et al. 1996). In a previous
study (Vikkula et al. 1996), we identified the endothelial-
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specific angiopoietin receptor TIE2/TEK, located on
9p21, as the cause of familial mucocutaneous VMs
(VMCMs [MIM 600195]).
Glomuvenous malformations (GVMs [MIM 138000],
also known as “venous malformations with glomus
cells,” or “glomangiomas”) are similar to VMs (Gorlin
et al. 1960; Gupta et al. 1965; Rudolph 1993; Boon et
al. 1999; Calvert et al. 1999; Vikkula et al. 2001), yet,
clinically, they are distinguishable: they have a cobble-
stone appearance (fig. 1A and B), they have a consis-
tency harder than that of VMs, and they are painful on
palpation (authors’ unpublished data). Histologically,
GVMs are distinguished by the presence of pathogno-
monic rounded cells—glomus cells—around the dis-
tended veinlike channels (fig. 1C–F) (Rudolph 1993;
Vikkula et al. 1998; Boon et al. 1999). The term “glo-
mus” (Latin for “ball”) stems from the morphologically
similar contractile cells of the Sucquet-Hoyer arterio-
venous anastomoses in glomus bodies that are in-
volved in cutaneous thermoregulation (Pepper and
Lantis 1977). Glomus cells in GVMs appear to be
incompletely or improperly differentiated vascular
SMCs (VSMCs), since they stain positively for SMC
a-actin (fig. 1F) and vimentin but are negative for
desmin, von Willebrand factor, and S-100 (Kato et
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Figure 1 Typical GVMs. A and B, Cutaneous GVMs of right
lower extremity in two patients, showing phenotypic variability. C,
Cross-section of normal vein (magnification 40#), stained with an-
tibody against SMC a-actin (red). D–F, Cross-sections of GVM (mag-
nifications 10#, 40#, and 40#, respectively), stained with either (D
and E) hematoxylin and eosin or (F) antibody to SMC a-actin (reddish
brown). Arrows indicate glomus cells; L p vascular lumens. A lesion
with somatic mutation is presented in panels A and D.
al. 1990). In addition, on electron microscopy, glomus
cells show smooth-muscle myofibrils and “dense bod-
ies” (Goodman and Abele 1971).
In a previous study, we showed, in five families, that
GVMs cosegregate with a 4–6-cM locus,VMGLOM, on
chromosome 1p21-22 (Boon et al. 1999), and we ex-
cluded three candidate genes in the region: DR1 (encod-
ing depressor of trancription 1), TGFBR3 (encoding
transforming growth factor-b receptor, type 3), and TFA
(encoding tissue factor). Four other families, with linkage
to a 24-cM region overlapping the VMGLOM locus,
were independently reported by another group (Calvert
et al. 2001). To localize new STSs and ESTs, we generated
YAC- and PAC-based physical maps (Brouillard et al.
2000). In seven additional families with linkage to the
region, we performed haplotype analysis and identified
linkage disequilibrium that narrowed the area to !1.48
Mb (Irrthum et al. 2001). Using STSs, we mapped three
new positional candidate genes to this region: EVI5 (the
proto-oncogene), GFI1 (the growth-factor–independ-
ence gene), and RPL5 (encoding ribosomal protein L5)
(Brouillard et al. 2000). Moreover, FAP48 (GenBank ac-
cession number U73704), which encodes an FKBP-as-
sociated protein of 48 kD, was localized to the region
on the basis of the sequence obtained from one end of
clone 775d17 that was used for construction of the PAC
map. Since FAP48 was easily amplifiable from lympho-
blast RNA, it was screened first. We identified several
mutations but, also, important discrepancies versus the
published FAP48 sequence. Therefore, we propose to call
this gene “glomulin.”
Subjects and Methods
Subjects
Informed consent was obtained from all family mem-
bers prior to their participation in the study and was
approved by the ethical committee of the medical faculty
at the Universite´ catholique de Louvain, Brussels. Twelve
families have been described elsewhere (Boon et al. 1999;
Irrthum et al. 2001). Among these, family Al (presented
by Irrthum et al. [2001]) was shown to have VMs, rather
than GVMs, according to a recent histological diagnosis
of a resected lesion. Herein, we present eight additional
families with individuals affected by GVMs, as well as
one sporadic case, BG, with no known family history of
the disease (fig. 2). Family members with anamnestic
notion of cutaneous lesions were clinically examined.
For genomic-DNA extraction, buccal-cell samples were
obtained from individuals Blo-52 and Blo-810, and ve-
nous blood samples were drawn from all other partic-
ipants. A second blood sample was obtained from some
individuals, for lymphocytic transformation with Ep-
stein-Barr virus. Immunohistochemistry was performed
as described elsewhere (Boon et al. 1999).
Northern Blots and RT-PCR
Hybridizations of the 12-Lane Human Multiple Tissue
Northern (MTN) Blot (Clontech Laboratories) and Hu-
manMultiple Tissue Expression (MTE)Array 2 (Clontech
Laboratories) were performed according to theMTE pro-
tocol provided by themanufacturer. Two different probes,
radiolabeled by random priming with a-[32]dCTP, were
used: full-length glomulin coding sequence and a 482-bp
5′ fragment thereof (nt 23 to 459). The filters were
either exposed to Biomax films (Kodak) or analyzed by
phosphorimager (Molecular Dynamics). For RT-PCR,
RNA extractions on eight GVM lesions and on skin, um-
bilical cord, and placenta were performed by standard
phenol/chloroform procedure (Chomczynski and Sacchi
1987), whereas the SV Total RNA isolation system (Pro-
mega) was used on cultured SMCs. Several combinations
of cDNAprimerswere used to amplify different fragments
of glomulin (sequences available on request).
5′ Rapid Amplification of cDNA Ends (RACE)
5′-RACE experiments were performedwith the 5′RACE
System for Rapid Amplification of cDNA Ends (Life
Technologies). The gene-specific primers used were 5′-
GCT GAT TCC AAA GGG TAG AC-3′, 5′-TGG GAT
Figure 2 Pedigrees of 20 families with GVMs, presented in order of occurrence of the mutations in glomulin. Individuals tested are
indicated by numerals. Blackened symbols denote affected patients, symbols containing a dot denote unaffected carriers, the half-blackened
symbol (in families Bln and Wi) denotes a phenocopy, and question marks (?) indicate that the status is unknown. The second-hit mutation,
980delCAGAA, in family Ad, also is indicated.
Brouillard et al.: Mutations in Glomulin Cause “Glomangiomas” 869
ATC TGT TTT CCA GAG-3′, and 5′-CTA TCC TCT
TTA TCT TTA CAC-3′.
Genomic Structure of the Glomulin Gene
Exon/intron boundaries for exon 4 were identified by
sequencing the SP6-end of the PAC clone 775d17 (Brouil-
lard et al. 2000). To define the remaining genomic struc-
ture, 36 primers were progressively designed on the basis
of the glomulin cDNA sequence (sequences available on
request). Different combinations of these exonic primers
were used for PCR on PAC clone 775d15 and on the
overlapping clone 1090n11 (Brouillard et al. 2000). To
identify exon/intron boundaries, interexonic fragments
obtained were completely or partially sequenced by either
a DNA4000 (Li-Cor) or a CEQ2000 (Beckman Coulter)
fluorescent sequencer.
Mutational Screening
cDNA.—RNA was extracted from a resected lesion in
individuals Ad-11, F-6, Sch-100, Ba-10, Ft-24, Ri, and
BG and/or from cultured, Epstein-Barr virus–transformed
lymphoblasts, by the SV Total RNA isolation system (Pro-
mega). cDNA synthesis, SSCP, and heteroduplex analyses
were performed as described elsewhere (Boon et al. 1999).
PCR primers were synthesized to cover the coding se-
quence of glomulin, in overlapping fragments of ∼250 bp
(sequences available on request).
Genomic DNA.—Thirty-eight intronic primers (se-
quences available on request) were synthesized from the
obtained genomic sequences, to amplify the 19 exons of
glomulin. Genomic DNA was screened by radioactive
SSCP and heteroduplex analysis for Ad-3, Ad-11 (tis-
sue), Al-14, Ba-10, BG, Chn-200, Del-2, Du-10, Ft-21,
Ke-10, Ly-100, Ri-12, Wi-14, and several control indi-
viduals, as described elsewhere (Boon et al. 1999). Am-
plified fragments were also loaded onto denaturing
5%-acrylamide sequencing gels, to identify potential
insertions or deletions. Fragments with abnormal mi-
gration were reamplified, purified, and sequenced on
a CEQ2000 capillary sequencer (Beckman Coulter).
The amplification product for somatic mutation
980delCAGAA was cloned into pBLSK (Stratagene),
for sequencing (fig. 3). Since the glomulin RT-PCR for
patients from family Ad showed several aberrant bands,
Elongase enzyme mix (Life Technologies) was used for
long-range genomic PCRs for deletion mapping. The
amplicon obtained with primers in introns 7 and 13 was
smaller than normal. It was sequenced to identify the
breakpoints (fig. 3). Since mutation 157delAAGAA was
identified in samples from families F and Sch, families
Bl, Bln, Bt, Sh, and T, which share the same haplotype
(Irrthum et al. 2001), were checked for that mutation
only.
Segregation of Mutations
Since most mutations create size differences, we used
sequencing gels to assess inheritance in the families. Mu-
tations modifying a restriction-enzyme cutting site were
checked by appropriate digestion: destruction of a NsiI
site for mutations 107insG and 108 CrA, creation of a
SpeI site for 554delA556delCCT, and destruction of a
XmnI site for 1711delGT. Since mutation 1547CrG did
not change either the amplicon size or any restriction
site, we synthesized wild-type and mutant primers (5′-
CTG CTT CAT AAT GTG CTT TT(C/G)- 3′) for allele-
specific PCR. These were used in combination with the
forward primer (5′-AGT AGG CAA TCA ATC ATT
GTT G-3′) of exon 17. The annealing temperature was
58C. A reverse primer (5′-AAT GGC TTA GCT GTT
ATG GTC-3′) of exon 17 was added to the reaction to
serve as an internal positive control and as competitor
to improve the specificity of the reaction. The 8.4-kb
deletion in family Ad was checked by PCR using a
primer (5′-TTG AGC ATG TTT ATA GCT GTT G-3′)
4 kb upstream of exon 8 and a reverse primer (5′-TAG
AGA TAG AGC AAT AAC TCA C-3′) of exon 14. This
produced a band of 2.7 kb, instead of 11.1 kb.
Computational Analyses
Nucleotide- and protein-database searches were per-
formed through the Web site of the National Council of
Biotechnology Information by BLAST searches blastn,
blastx, and tblastn, with nonredundant databases, dbEST,
species-specific databases, high-throughput genomic se-
quences, and genome-survey sequences. SMART and
PredictProtein were used to identify functional domains.
Results
Identification of the Glomulin Gene
During our positional cloning efforts, we sequenced the
ends of several PAC clones of the haplotype-shared area
(Brouillard et al. 2000), and, by a BLAST search with the
sequences from the SP6 end of PAC 775d17, we identified
some ESTs and the cDNA for FAP48. FAP48 had been
cloned from a Jurkat-cell library by a yeast–two-hybrid
screen, by use of the immunosuppressant drug-binding
domain of a rabbit immunophilin, FKBP59, as bait
(Chambraud et al. 1996). We amplified and sequenced
FAP48 from lymphoblasts, various tissues, and Jurkat
cells. In all the cDNA samples tested, an 85-bp exon (po-
sition 1215 downstream of the ATG), which was not
present in the published FAP48 sequence, and a single G
at position 1479–1480 were observed (shown in fig. 4).
Both of these changes modify the open reading frame,
resulting in a larger protein, comprising 594 amino acids
instead of the reported 417 amino acids (i.e., 68 kD vs.
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Figure 3 Glomulin mutations. Control sequence (upper chromatograms) is compared with mutant sequence (lower chromatograms).
Asterisks (*) indicate chromatograms showing reverse-strand sequence. Sequences presented for large genomic deletions and for the second-hit
mutation, 980delCAGAA, were obtained from cloned fragments. Arrows indicate site(s) of mutation.
48 kD). Since the new, larger protein is significantly dif-
ferent from FAP48 i.e., it is 32% longer, and the 12
most–carboxy-terminal amino acids of FAP48 are dis-
cordant, and since we here show that mutations in the
sequence encoding the 68-kD protein are responsible for
GMVs, we propose to name this novel factor “glomulin”
(GenBank accession number AJ302735).
Structure and Expression Profile of Glomulin
Prior to screening for mutations, we established the
genomic structure of glomulin (fig. 4). The gene is com-
posed of 19 exons and extends over 55 kb (GenBank
accession numbers AJ302727–AJ30273); exon 1 is non-
coding, exon 2 contains the translation start site, and
exon 19 contains the TGA stop codon. Expression of
glomulin is ubiquitous, on the basis of northern blot
hybridizations (fig. 5). One major transcript of ∼2 kb,
corresponding to the size (1,785 nt) of glomulin coding
sequence, was observed in all 12 human tissues on the
MTN filter (fig. 5). An additional band, of ∼3 kb, was
present in most of the tissues. Since we found a single
5′-RACE product, which contained an in-frame stop co-
don 81 nt upstream of ATG, the second band is unlikely
to result from splice variations in the 5′ region.Glomulin
was also detected in all 75 tissues present on the MTE
filter (data not shown). In addition, with RT-PCR, tran-
scripts were found in all eight GVM lesions tested, as
well as in cultured SMCs, normal skin, umbilical cord,
and placenta (data not shown).
Inherited Mutations
Screening for mutations in glomulin was performed
on genomic DNA extracted from blood and/or on
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Figure 4 Glomulin gene—structure and mutations. The sizes of exons and of the three largest introns are given; other introns are to
scale. Exon 1 is noncoding (n c), exon 2 contains the translation start site, and exon 19 contains the TGA stop codon. Above the sequence
line, the white arrowheads indicate differences versus FAP48 cDNA (i.e., a new, 85-bp exon and an extra G), the single asterisk (*) indicates
a single amino acid deletion, the double asterisks (**) indicate a splice-site mutation, and the box indicates the second-hit mutation,
980delCAGAA; the other three mutations cause immediate stop codons. Below the sequence line, frameshift mutations leading to premature
stop codons are indicated, as are sequences of breakpoints of 8.4-kb deletion with GG insertion. The “FAP48” line indicates exons encoding
FAP48.
cDNA produced from RNA extracted from either re-
sected GVMs or cultured lymphoblasts. We identified
14 different germline mutations in patients from 20 un-
related families (figs. 2–4). One mutation, (IVS72884)–
(IVS13255)del8.4kbinsGG, is an 8.4-kb genomic
deletion removing exons 8–13. Ten of the mutations
were deletions or insertions that cause frameshifts re-
sulting in premature stop codons. Of these 10mutations,
157delAAGAA was present in all seven families (i.e.,
families Bl, Bln, Bt, F, Sch, Sh, and T; fig. 2) in which
we previously had found strong evidence for linkage
disequilibrium, proving the ancestral origin of the iden-
tified haplotype (Irrthum et al. 2001). Another deletion,
IVS64delA, affects an adenine at the 4 position of
the consensus donor splice-site sequence of intron 6.
This should interfere with splicing of exon 6 and prob-
ably results in skipping of the 238-bp exon, which
would modify the reading frame and result in a pre-
mature stop codon. However, no RNA was available
from this family to confirm this. Two nonsense mu-
tations were also detected: 108CrA in a TGC codon
and 1547CrG in a TCA codon. The only mutation that
would not cause a premature stop codon was a deletion
of 3 nt (1179delCAA), equivalent to the removal of an
asparagine at position 394.
No mutation was found in family Al, which we had
reported elsewhere (Irrthum et al. 2001). This result is
in accordance with the histological analysis of a recently
resected lesion in which no glomus cells were identified:
since the mutations in families Ad, Ba, and Del (fig. 2),
all three of which share with family Al a putative hap-
lotype B in the VMGLOM locus, are different, this find-
ing confirms the hypothesis that a similar haplotype is
shared by chance in these four families (Irrthum et al.
2001). Overall, we have identified a mutation for all five
pedigrees (i.e., Bl, Bt, F, Sh, and T) reported by Boon et
al. (1999), for all six families (Ad, Ba, Bln, Del, Lml,
and Sch) with GVM (of the seven families studied) re-
ported by Irrthum et al. (2001), and for all seven of the
pedigrees newly reported here (fig. 2).
Penetrance and Somatic Second Hit
Cosegregation experiments in all pedigrees allowed
the detection of a total of 18 unaffected carriers and 2
phenocopies (i.e., affected individuals without the in-
herited mutation) (fig. 2). Patient Wi-11 is considered to
be “affected” on the basis of anamnestic information
only, since no clinical examination was performed, and
patient Bln-1040 had only a single small (i.e., !5-mm)
lesion in the pubic area. Among the carriers, a bluish
cutaneous lesion in patient Du-21 was resected when the
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Figure 5 Glomulin northern blot analysis—human MTN blot
(Clontech) hybridized with a 482-bp 5′ probe of glomulin. Each lane
contains 1 mg polyA RNA from adult tissue. Similar results were
obtained with a full-length glomulin probe. Lower gel, b-actin control.
individual was young, but no histological results were
available; thus, she could be affected. Moreover, patients
Ly-10 and Ly-12 had extensive varicose veins that could
hide a GVM. Unaffected carriers Lml-223, Blo-4, and
Ft-2 were not examined. Overall, the observed pene-
trance of the mutations was 88.6% and rose to 92.7%
at age 20 years.
Interestingly, in addition to the inherited large ge-
nomic deletion found in family Ad (figs. 2–4), a 5-bp
deletion in the unlinked allele was identified in DNA
from a lesion in patient Ad-11 (figs. 1A and D, 2–4).
This change was present only in the DNA and RNA
extracted from the resected tissue, not in cells from
blood, and, moreover, none of the other members of
family Ad had this 5-bp deletion; thus, this mutation
must represent a somatic “second hit.”
In Silico Analysis of Glomulin
Database searches with the glomulin-coding sequence
did not identify either a signal sequence or any other
functional or conserved domain. Partial sequence iden-
tity with exons 6–11 was found in DNA from human
chromosome 21, but no corresponding ESTs could be
retrieved. Thus, this partial paralogue is likely a pseu-
dogene. In human, mouse, and rat, only ESTs with a
high degree of similarity to glomulin were found. We
retrieved putative genes with significant homologies in
Drosophila melanogaster, Danio rerio, Xenopus laevis,
Tetraodon nigroviridis, andArabidopsis thaliana, but no
significant alignments were found in the complete ge-
nomic sequences of lower organisms, such as Caenor-
habditis elegans, Saccharomyces cerevisiae, or Escheri-
chia coli. In the putative promoter of the human
glomulin gene (deduced from sequences in the public
databases), we identified a CArG-like element (Shimizu
et al. 1995), often present in promoters of genes ex-
pressed in SMCs.
Discussion
The data that have been presented clearly demonstrate
that mutations in glomulin are the cause of GVMs. Since
the first truncating mutation occurs as early as at the
first 31 bp of coding sequence, the disease is very likely
due to loss of glomulin function; however, the expres-
sivity of the phenotype is variable for the samemutation,
and not all individuals harboring a mutation are affected
(fig. 2). Thus, haploinsufficiency is not sufficient to ex-
plain the ethiopathogenesis of GVMs. In fact, we have
shown that a mutation on the second allele is needed,
suggesting that GVM lesions are caused by complete,
localized loss of glomulin function. The defined nature
and the variability, in both number and size, of the le-
sions (authors’ unpublished data) could be explained by
the frequency and the time of appearance of somatic
mutations; however, additional tissue samples must be
collected in order to prove this promising hypothesis.
Indeed, cellular heterogeneity of GVMs may be impor-
tant for the detection of somatic mutation. The lesion
in family Ad contained a high number of glomus cells
(fig. 1D), which may explain the fact that, to date, a
somatic mutation has been identified only in that tissue.
It also remains to be revealed why, despite the ubiquitous
tissue distribution of glomulin, only cutaneous lesions
are seen in patients with GVMs.
Since only individuals who reported having cutaneous
lesions were examined, it could be that many of the
unaffected carriers have a small, asymptomatic lesion.
However, since it is known that lesions may not be
obvious at birth and may appear later in life (Enjolras
and Mulliken 1996) and that the condition may express
as only a single tiny blue lesion anywhere on the body
(Boon et al. 1999), this could explain the unaffected
status of the younger carriers, such as Sch-1020 (ex-
amined at age 1 year), Bln-1070 (examined at age 2
years), Blo-52 (examined at age 12 years), Blo-51 (ex-
amined at age 14 years), Lml-223 (examined at age 14
years), and Chn-201 (examined at age 18 years).
To date, little is known about glomulin. Since no
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paralogues were identified on the basis of database
searches, glomulin seems to be unique and not amember
of a family of homologous genes. Glomulin seems to
be present only in higher organisms, such as vertebrates
and the fly. One possible partial homologue in humans
is FAP48; however, in the tested cDNAs, we have not
found any transcript specific for this protein, nor have
we found any FAP48-specific EST in the databases.
Since mutations in the glomulin gene result in GVMs
regardless of whether they would affect the coding se-
quence of FAP48, the development of GVMs is inde-
pendent of FAP48.
The primary cellular defect in GVMs is the presence
of the SMC-like glomus cells. As mesenchymal cells dif-
ferentiate and acquire an elongated cell shape, they ex-
press markers such as SMC a-actin, desmin, calponin,
SM22, and SM myosin (Yang et al. 1999). Glomus cells
express many SMC markers, and, as shown by electron
microscopy, they display a cellular structure reminiscent
of that of SMCs (Goodman and Abele 1971; Miettinen
et al. 1983). However, glomus cells are round or poly-
gonal (Goodman and Abele 1971; Kato et al. 1990). In
addition, whereas SMCs of normal veins express desmin
(Nanaev et al. 1991), glomus cells do not (Miettinen et
al. 1983). This partial expression of VSMC markers,
associated with an abnormal morphology and mural
organization, suggests that the important role of glo-
mulin is played at a late stage in VSMC maturation.
Although the cell type(s) expressing glomulin re-
main(s) to be defined, loss of function seems to be the
cause of the specific VSMC phenotype. This effect can
be direct, since we found that VSMCs express glomulin.
Furthermore, the glomulin gene contains a CArG-like
element in its promoter (i.e., one A/T is replaced by a
G or a C). The same motif is present in SMC-expressed
genes, such as a-actin and myosin heavy chains (Hill
and Treisman 1995; Miano et al. 2000). Thus, glomulin
could have a cell-type–specific expression pattern that
would explain why mutations in glomulin affect only
VSMCs.
If glomulin has interactions similar to those shown
for FAP48 (a truncated form of glomulin), it is inter-
esting to note that, in vitro and in vivo, in a yeast-two-
hybrid system, FAP48 interacts with FKBP59 and
FKBP12 (Chambraud et al. 1996). FKBP12 is known
to bind to—and, thereby, inhibit signaling through—the
TGFb type I receptor (TbRI) (Chen et al. 1997), and
TGFb signaling is important for both SMC maturation
and expression of SMC cytoskeletal markers. Indeed,
TbRI-deficient murine embryos lack SMCs around en-
dothelial-lined yolk-sac vessels (Larsson et al. 2001),
and, when endothelial cells and SMCs are cocultured
with an antibody to TGFb, SMC differentiation does
not occur (Hirschi et al. 1998). Glomulin, like FAP48,
may function to repress this inhibition. Accordingly,
complete loss of glomulin function would result in
increased binding of FKBP12 to TGFb receptors, in-
hibition of TGFb signaling, altered expression of
SMC proteins such as desmin, and altered differen-
tiation of VSMCs.
In summary, the data that have been presented here
demonstrate that a novel gene, glomulin, plays a role
in normal VSMC differentiation, since mutations in this
gene are responsible for the presence of SMC-like glo-
mus cells in inherited GVMs (“glomangiomas”). De-
velopmental studies of normal and glomulin-deficient
mice, as well as functional studies of resected GVM
tissues and of in vitro expression systems are needed
to get further insights into the role and function of
glomulin in both vascular morphogenesis and vascular
pathologies.
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